Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS (HIK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Hikma Announces Tie-Up With Vectura; Raises Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2018 | 03:12am EST

By Carlo Martuscelli

Hikma Pharmaceuticals announced Thursday a tie-up with inhaler producer Vectura Group to collaborate on the development of generic versions of GlaxoSmithKline Ellipta drugs.

Hikma also raised its guidance on the back of a strong performance in its injectables division. The generic drug manufacturer said it now sees revenue from the medicine group in the range of $825 million to $850 million, with a core injectables operating margin of between 39%gene and 40%.

The company said Vectura's inhaler technology has the potential to be developed into a generic version of the Ellipta portfolio--a group of drugs for the treatment of chronic obstructive pulmonary disease and asthma. The deal includes the development of at least three drugs in the portfolio, with first priority going to developing a generic version of Breo Ellipta.

Under the terms of the deal Hikma will make an upfront payment of $15 million to Vectura. Vectura will develop the device and formulation, while Hikma will be responsible for clinical development, the regulatory process and commercialization, Hikma said.

Once the first product is delivered to the company's facilities to enable clinical manufacturing, Hikma will make a $5 million payment to Vectura followed by milestone payments of up to $75 million at various stages of development.

Once the products are developed Hikma said it will pay net profit up to a mid-teen percentage for each product, plus sales milestone payments. Vectura in turn will pay up to $70 million for development activities, Hikma said.

The company noted the generic respiratory market is a key area of focus for the company and said its injectables division continues to perform ahead of expectations.

"While the US retail market remains challenging, with continued price erosion, the recent commercial and operational improvements we have made to our business are enabling us to deliver strong growth from our more differentiated portfolio," it said.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 1.05% 17.132 Delayed Quote.3.02%
GLAXOSMITHKLINE 1.13% 1498.6 Delayed Quote.0.50%
HIKMA PHARMACEUTICALS -0.16% 1547.5 Delayed Quote.-9.82%
VECTURA GROUP PLC -0.26% 75.75 Delayed Quote.8.21%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS
01/03Vectura hopes new respiratory device will breathe life into business
RE
01/03HIKMA PHARMACEUTICALS : UPDATE - Hikma Pharmaceutical Plants Sold to Investor Gr..
AQ
2018LONDON STOCK EXCHANGE : FTSE 100 slightly lower in fitting farewell to dim 2018
RE
2018EUROPE MARKETS: Stoxx Europe 600 Avoids Bear-market Close As U.S. Stocks Swoo..
DJ
2018HIKMA PHARMACEUTICALS : launches Dalfampridine Extended-release Tablets
AQ
2018Hikma To Join London's Blue-Chip Index as Shire Exits
DJ
2018HIKMA PHARMACEUTICALS : launches Clobazam Oral Suspension and Clobazam Tablets
AQ
2018HIKMA PHARMACEUTICALS : demonstrates support for US pharmacists and patient safe..
AQ
2018HIKMA PHARMACEUTICALS : Demonstrates Support for US Pharmacists and Patient Safe..
BU
2018Royal Mail seen dropping out of top British stock index
RE
More news
Financials ($)
Sales 2018 2 074 M
EBIT 2018 447 M
Net income 2018 271 M
Debt 2018 376 M
Yield 2018 1,92%
P/E ratio 2018 17,90
P/E ratio 2019 17,29
EV / Sales 2018 2,52x
EV / Sales 2019 2,41x
Capitalization 4 851 M
Chart HIKMA PHARMACEUTICALS
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 24,5 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer & Director
Said Samih Taleb Darwazah Executive Chairman
Khalid Walid Hosni Nabilsi Chief Financial Officer
Surendera Tyagi Chief Scientific Officer, Global Head-R&D
Bryan Hotston Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS-9.82%4 851
JOHNSON & JOHNSON0.03%350 508
PFIZER-2.70%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291